Adlai Nortye Ltd.

NASDAQ: ANL · Healthcare · Biotechnology

PublicHQ Grand Cayman, CIK 0001944552Reports USD

#1 of 1,406 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 50

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$51.9M

Employees

109

Market cap

$602.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$51.9M-$51.9M2024

Total assets$71.3M$71.3M2024

Liabilities$45.8M$45.8M2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Adlai Nortye Ltd. earned -$51.9M in FY2024 net income.

Peers · Healthcare

Cytek Biosciences, Inc.58C Fulgent Genetics, Inc.68B CytomX Therapeutics, Inc.63C MiMedx Group, Inc.85A

Key facts

CEOYang Lu

SectorHealthcare

IndustryBiotechnology

HeadquartersGrand Cayman, null

ExchangeNASDAQ: ANL

Employees109

IPO date2023-09-29

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.